Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.35 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.35 |
| ▸ | HTR1F | P30939 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | IL2 | P60568 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16362095 | 0.97 | KDM1A (0.39) | KDM1ACYP11B2GPR55CRACR2AHTR1F | |
| SCHEMBL17766345 | 0.88 | CRACR2A (0.42) | KDM1ACRACR2AALDH1A1HPGDSTIM1 | |
| SCHEMBL17766354 | 0.84 | CYP11B2 (0.39) | KDM1ACYP11B2GPR55ALDH1A1HPGD | |
| SCHEMBL17766361 | 0.83 | CYP11B2 (0.39) | KDM1ACYP11B2GPR55ALDH1A1HPGD | |
| SCHEMBL17766400 | 0.79 | IL2 (0.53) | CRACR2ASTIM1ORAI1IL2 | |
| SCHEMBL17766405 | 0.79 | IL2 (0.49) | GPR55CRACR2AHTR1FSTIM1ORAI1 | |
| SCHEMBL16362422 | 0.77 | PTGER3 (0.39) | CYP11B2GPR55 | |
| SCHEMBL16362059 | 0.77 | PTGER3 (0.39) | CYP11B2GPR55CRACR2AHTR1FHTR1A | |
| SCHEMBL17766394 | 0.76 | IL2 (0.45) | ALDH1A1HPGDSTIM1ORAI1MAPT | |
| SCHEMBL17766376 | 0.76 | STIM1 (0.46) | STIM1ORAI1MAPTIL2ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | claimed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | claimed |
| EP-3010586-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2016-04-27 | — | — | EP | claimed |
| WO-2014203217-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | claimed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | RYR2, NR2C2, CACNA1E | KDM1A 2892/4885CYP11B2 623/4885GPR55 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.